Showing 1 - 7 results of 7 for search 'Naomi B. Haas', query time: 0.03s
Refine Results
-
1
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial by Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese-Bullock, Margaret von Mehren, Naomi B. Haas, Merrick I. Ross, Lynn T. Dengel, Craig L. Slingluff
Published 2024-03-01
Article -
2
Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial by Caitlin C. Murphy, Hannah M. Fullington, David E. Gerber, Isaac Alex Bowman, Maneka Puligandla, Janice P. Dutcher, Robert S. DiPaola, Naomi B. Haas
Published 2021-09-01
Article -
3
-
4
1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma by Michael Hurwitz, Elizabeth Plimack, Jeffrey Sosman, Sabina Signoretti, David F McDermott, Michael B Atkins, Naomi B Haas, Hans Hammers, Nicholas Schindler, Opeyemi A Jegede, Catherine J Wu, David Braun, Miya Hugaboom, Kelly Street, Neil Ruthen, Lena Wirth
Published 2023-11-01Article -
5
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) by Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano
Published 2024-04-01
Article -
6
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors by David Hong, Manish Sharma, Erminia Massarelli, Heather Kinkead, Naomi B Haas, Rachel E Sanborn, Ralph J Hauke, Anthony W Tolcher, Neal Akhave, Jong Chul Park, Jennifer Carlisle, John Hamm, Alexander I Spira, David Berz, Vasily Andrianov, Brianne O’Neill, Justin A Call, Frank Yung-Chin Tsai, D Ross Camidge
Published 2023-11-01Article -
7
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) by Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Published 2023-03-01
Article